ADP受体阻滞剂的临床研究进展

被引：5

作者：

孙黎

施安国

机构：

[1] 上海第二医科大学附属仁济医院临床药理药学研究室

[2] 上海第二医科大学附属仁济医院临床药理药学研究室上海

[3] 上海

来源：

中国临床药理学杂志 | 2002年 / 04期

关键词：

噻吩并吡啶; 噻氯吡啶; 氯吡格雷;

D O I：

10.13699/j.cnki.1001-6821.2002.04.017

中图分类号：

R969 [临床药理学];

学科分类号：

100602 ; 100706 ;

摘要：

阿斯匹林（Asp）通过单一的途径影响血小板的作用,几十年来一直是抗血小板治疗的主要药物,对心血管有不完全的保护作用,但阿斯匹林影响了血管紧张素转换酶抑制剂的血液动力学。双嘧达莫（潘生丁）有辅助的治疗作用,但没有迹象表明单用双嘧达莫或与阿斯匹林一起用比单独服用标准剂量的阿斯匹林更有效。口服血小板糖蛋白Ⅱb/Ⅲa受体阻滞剂,最初被认为很有希望,但在最近的临床试验中的结果却令人失望。新一代药物一噻吩并吡啶,通过阻滞5’-二磷酸腺苷（ADP）受体,抑制了血小板的活性。本文讨论了该类药物的药理作用、临床研究和应用价值,包括噻氯吡啶和氯吡格雷。5’-二磷酸腺苷受体阻滞剂通过另外的途径抑制了血小板的活性,在防治心血管疾病方面比阿斯匹林更有效。

引用

页码：306 / 309+316 +316

页数：5

共 11 条

[1]

Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy[J] . Khatereh Moshfegh,Maurice Redondo,Friedgard Julmy,Walter A Wuillemin,Mathias U Gebauer,André Haeberli,Beat J Meyer.Journal of the American College of Cardiology . 2000 (3)

[2] Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease [J].

Peterson, JG ;

Topol, EJ ;

Sapp, SK ;

Young, JB ;

Lincoff, AM ;

Lauer, MS .

AMERICAN JOURNAL OF MEDICINE, 2000, 109 (05) :371-377

[3]

Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial[J] . The Lancet . 2000 (9201)

[4] Clopidogrel versus ticlopidine after intracoronary stent placement [J].

Berger, PB ;

Bell, MR ;

Rihal, CS ;

Ting, H ;

Barsness, G ;

Garratt, K ;

Bellot, V ;

Mathew, V ;

Melby, S ;

Hammes, L ;

Grill, D ;

Holmes, DR .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (07) :1891-1894

[5]

Randomized Evaluation of Anticoagulation Versus Antiplatelet Therapy After Coronary Stent Implantation in High-Risk Patients: The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS)[J] . Philip Urban,Carlos Macaya,Hans-Jurgen Rupprecht,Ferdinand Kiemeneij,Hakan Emanuelsson,Alessandro Fontanelli,Michael Pieper,Thea Wesseling,Luc Sagnard.Circulation . 1998 (20)

[6]

Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting: The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study[J] . Michel E. Bertrand,Victor Legrand,Jean Boland,Eckart Fleck,Johannes Bonnier,Hakan Emmanuelson,Matty Vrolix,Luc Missault,Sergio Chierchia,Michele Casaccia,Luigi Niccoli,Ali Oto,Christopher White,Michael Webb-Peploe,Eric Van Belle,Eugene P. McFadden.Circulation . 1998 (16)

[7]

Antiplatelet Agents and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction (SOLVD) Trial[J] . Ayman S Al-Khadra,Deeb N Salem,William M Rand,James E Udelson,John J Smith,Marvin A Konstam.Journal of the American College of Cardiology . 1998 (2)

[8]

Comparison of Antiplatelet Effects of Aspirin, Ticlopidine, or Their Combination After Stent Implantation[J] . Hans J. Rupprecht,Harald Darius,Ulrike Borkowski,Thomas Voigtlander,Bernd Nowak,Sabine Genth,Jurgen Meyer.Circulation . 1998 (11)

[9]

Effects of antiplatelet drugs on dialysis-associated platelet deposition in polytetrafluoroethylene grafts[J] . David W. Windus,Samuel A. Santoro,Ralph Atkinson,Henry D. Royal.American Journal of Kidney Diseases . 1997 (4)

[10] Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting [J].

Goods, CM ;

AlShaibi, KF ;

Liu, MW ;

Yadav, JS ;

Mathur, A ;

Jain, SP ;

Dean, LS ;

Iyer, SS ;

Parks, JM ;

Roubin, GS .

AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (09) :1042-1044

← 1 2 →